Kim, Jeong Rae Choi, Yongwhan Kim, Dong-Hwee Yoon, Hong Yeol Kim, Kwang meyung 2024-01-12T02:37:23Z 2024-01-12T02:37:23Z 2022-09-15 2022-09 1999-4923 https://pubs.kist.re.kr/handle/201004/76022 Various immunotherapeutic agents that can elicit antitumor immune responses have recently been developed with the potential for improved efficacy in treating cancer. However, insufficient delivery efficiency at the tumor site, along with severe side effects after systemic administration of these anticancer agents, have hindered their therapeutic application in cancer immunotherapy. Hydrogels that can be directly injected into tumor sites have been developed to help modulate or elicit antitumor responses. Based on the biocompatibility, degradability, and controllable mechanochemical properties of these injectable hydrogels, various types of immunotherapeutic agents, such as hydrophobic anticancer drugs, cytokines, antigens, and adjuvants, have been easily and effectively encapsulated, resulting in the successful elicitation of antitumor immune responses and the retention of long-term immunotherapeutic efficacy following administration. This review summarizes recent advances in combination immunotherapy involving injectable hydrogel-based chemoimmunotherapy, photoimmunotherapy, and radioimmunotherapy. Finally, we briefly discuss the current limitations and future perspectives on injectable hydrogels for the effective combination immunotherapy of tumors. English Multidisciplinary Digital Publishing Institute (MDPI) Injectable Hydrogel-Based Combination Cancer Immunotherapy for Overcoming Localized Therapeutic Efficacy Article 10.3390/pharmaceutics14091908 1 Pharmaceutics, v.14, no.9 Pharmaceutics 14 9 Y scie scopus 000857010400001 Pharmacology & Pharmacy Pharmacology & Pharmacy Review IMMUNE CHECKPOINT BLOCKADE IMMUNOGENIC CELL-DEATH DRUG-DELIVERY-SYSTEMS SUSTAINED CO-DELIVERY DENDRITIC CELLS NANOPARTICLES ANTITUMOR DESIGN RADIOISOTOPE MECHANISMS injectable hydrogel cancer immunotherapy drug delivery